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Migration and proliferation of smooth muscle 
cells are key to a number of physiological and 
pathological processes, including wound 
healing and the narrowing of the vessel wall. 
Previous work has shown links between 
inflammatory stimuli and vascular smooth 
muscle cell proliferation and migration 
through mitogen activated protein kinase 
(MAPK) activation, though the molecular 
mechanisms of this process are poorly 
understood. 
Here we report that tribbles-1, a recently 
described modulator of MAPK activation 
controls vascular smooth muscle cell 
proliferation and chemotaxis via the Jun 
Kinase pathway. Our findings demonstrate 
that this regulation takes place via direct 
interactions between tribbles-1 and 
MKK4/SEK1, a Jun activator kinase. The 
activity of this kinase is dependent on 
tribbles-1 levels, whilst the activation and the 
expression of MKK4/SEK1 is not. In 
addition, tribbles-1 expression is elevated in 
human atherosclerotic arteries compared to 
non-atherosclerotic controls, suggesting that 
this protein may pay a role in disease in vivo. 
In summary, the data presented here suggest 
an important regulatory role for trb-1 in 
vascular smooth muscle cell biology. 
 Injury to the arterial wall initiates a 
series of changes in specialised molecular and 
cellular events that not only contribute to wound 
healing but to the pathogenesis of 
atherosclerosis, the presentation of acute 
coronary syndromes (ACS) and the 
complications of percutaneous coronary 
intervention (PCI). An important initiating event 
appears to be endothelial cell dysfunction or cell 
death caused by local abnormalities. These events 
result in the production and release of a number of 
inflammatory cytokines and chemokines. In 
pathogenic conditions, elevated levels of 
inflammatory mediators can lead to migration and 
proliferation of vascular smooth muscle cells 
(VSMC) to form a neointima. These cellular 
responses are mediated via the co-ordinated action 
of various second messenger pathways, including 
activation of Mitogen Activated Protein Kinase 
(MAPK) cascades and IκB kinases. Activation of 
these systems has been reported in several 
pathological conditions of vessel walls (1-3). 
MAPKs are involved in the regulation of 
development, cell activation, proliferation and 
vascular contraction (4-7). Further, they are central 
in regulating VSMC activation. It has been 
demonstrated that activation of MAPK cascades 
occurs in response to a wide range of stimuli, 
including pro-inflammatory cytokines, growth 
factors, mechanical stimuli (stress) (8) and integrin-
dependent cell/matrix interactions (9, 10). MAPKs 
are classified into at least three distinct groups (JNK, 
p38 and ERK kinases) and can be activated via a 
variety of upstream kinases, MAPKKs. In VSMC, 
Jun kinases (JNK) and p38 MAPKs have been 
implicated in responses primarily to stress (heat, 
hypoxia, chemical, oxidative, etc.) and pro-
inflammatory cytokines, extracellular signal 
regulated protein kinases (ERK) primarily respond 
to mitogenic stimuli such as growth factors (PDGF) 
(11), oxidised LDL (12) or Ang II (reviewed in 
(13)). However, in most cases a given stimulus will 
activate more than one group of MAPKs. The 
specific contribution of each MAPK pathway to a 
physiological response varies from cell type to cell 
type. In some cases, MAPK pathways can co-
operate, but they can antagonise in others (14, 15). 
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However, the mechanisms which are responsible 
for these differences in MAPK responses in 
VSMC are largely unknown. 
 We have recently reported the 
identification (16, 17) and characterisation of a 
novel protein family, human tribbles (trb) as 
regulators of MAPKK activity (16, 18). We have 
shown that trb-1 and trb-3 are able to bind to 
various MAPKKs and that their concentration 
regulates preferential activation of the different 
MAPK pathways, presumably leading to 
different cellular responses (18). Drosophila and 
Xenopus Tribbles have been shown to regulate 
cell cycle progression during embryonic 
development (19-22). Murine trb-3 has been 
demonstrated to inhibit insulin-dependent 
activation of Akt and was suggested to play a 
role in the development of diabetes in a mouse 
model (23, 24). However, recent conflicting data 
suggest that this proposed role may require 
further clarification (25). Further, the importance 
of human tribbles proteins in cell physiology has 
not been evaluated. Here we report that trb-1 is 
selectively overexpressed in chronically 
inflamed human atherosclerotic arteries and that 
it regulates vascular smooth muscle cell 
proliferation and chemotaxis via the JNK 
pathway. These observations define trb-1 as a 
novel, central regulator of VSMC function. 
 
EXPERIMENTAL PROCEDURES 
All the experiments described in this study were 
performed multiple times (N>2) and 
representative datasets are shown. 
 
Ethics: 
The human samples were obtained under the 
ethical approval granted by the North Sheffield 
Research Ethics Committee. This study 
conforms to the principles outlined in the 
Declaration of Helsinki. 
 
Plasmids, siRNA 
Trb-1 overexpression plasmid has been 
described before (18). siRNA SmartPool against 
human trb-1 was purchased from Dharmacon 
and used according to the manufacturer’s 
recommendation. Plasmids for yellow 
fluorescent protein (YFP)-based protein 
fragment complementation assay (PCA) (42, 43) 
were a kind gift of Prof. S. Michnik and have been 
described before (26). 
 
Cell culture and the stimulation with LPS 
VSMC were purchased from Cascade Biologics and 
maintained in Medium 231 with smooth muscle 
growth supplement (all from Cascade Biologics). 
VSMC were plated in 6 well plates at an initial 
density of 0.5×105 cells/well in 2 ml of complete 
growth media. 24 hours post transfection cells were 
stimulated by 100 ng/ml LPS, as stated in the 
figures. HeLa cells (ATCC) were maintained in 
DMEM medium (Invitrogen), containing 10% 
Foetal Bovine Serum (Biowhittaker), 5mM of 
sodium pyruvate and 100 µg/ml of penicillin and 
streptomycin (Sigma).  
 
Artery biopsies 
Coronary arteries from patients with a diagnosis of 
ischemic heart disease (IHD, n=8) and dilated 
cardiomyopathy (DCM, n=6) were harvested from 
transplantation recipients at the time of surgery. 
Patients diagnosed as having DCM were free of 
CAD before transplantation, as assessed by coronary 
angiography and histological analysis by a cardiac 
pathologist (SKS) using the American Heart 
Association (AHA) classification system (27-29). 
All patients were men and white in origin. Mean 
ages were 55.75 ±5.11 for IHD and 48.5±10.23 for 
the DCM group. Mean AHA histological grades of 
disease were 6.42 for the IHD and 3.16 for the DCM 
group, respectively. 
 
RNA isolation and Quantitative Real-time PCR 
analysis 
Total RNA was extracted from human artery 
biopsies and VSMC using RNeasy kit (Qiagen) 
according to the manufacturer's protocol. 2µg RNA 
was reverse transcribed into first strand cDNA and 
used immediately for qRT-PCR. Gene expression 
was analyzed by qRT-PCR using ABI prism 7900 
(Applied Biosystems). Probes for human trbs, IL-1
?, IL-RA, TNF? and GAPDH were synthesized 
by Sigma Genosys with FAM at the 5’-end and 
TAMRA at the 3’-end. The sequences of all primers 
and probes used are listed below. 
 
Targe
t   Sequence(5'-3') 
htrb-1 Forw CCCCAAAGCCAGGTGCCT 
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ard 
  
Rever
se TACCCGGGTTCCAAGACG 
  Probe 
FAM-
CAGCCTCTTGAGACGGGA
-TAMRA 
htrb-2 
Forw
ard 
CATACACAGGTCTACCCC
C 
  
Rever
se TCCGCGGACCTTATAGAC 
  Probe 
FAM-
CTTCGAAATCCTGGGTTT
T-TAMRA 
htrb-3 
Forw
ard CTGCCCGCTGTCTGGTTC 
  
Rever
se GGGCATCGGGTCCTGTCG 
  Probe 
FAM-
TGCCTCCTTCGTCGGGAG-
TAMRA 
IL-1
? 
Forw
ard 
ACAGATGAAGTGCTCCTT
CCA 
  
Rever
se 
GTCGGAGATTCGTAGCTG
GAT 
  Probe 
FAM-
CTCTGCCCTCTGGATGGC
GG-TAMRA 
IL-
RA 
Forw
ard GAAGATGTGCCTGTCCTG 
  
Rever
se CGCTCAGGTCAGTGATGT 
  Probe 
FAM-
TGGTGATGAGACCAGACT
-TAMRA 
GAP
DH 
Forw
ard GCCTTCCGTGTCCCCACT 
  
Rever
se TGAGGGGGCCCTCCGACG 
  Probe 
FAM-
CCTGCTTCACCACCTTCTT
-TAMRA 
 
To quantify transcripts for genes of interest, we 
used the GAPDH transcript as an internal 
control, and each sample was normalized with 
respect to GAPDH transcript content. Standard 
curves for the 9 genes and GAPDH mRNAs 
were generated using serially diluted solution of 
plasmids incorporating each gene as a PCR 
template. All assays were performed in duplicate and 
the average values were used for analysis. 
 
Transfections: 
Transfections were performed using Nucleofector 
(Amaxa) using program U-25 and Nucleofector 
solution for VSMC (Amaxa). For most experiments, 
1.0 × 106 cells were used per nucleofection. The rate 
of transfection was >40 as judged by EGFP 
expression, measured by fluorescent microscopy 
(data not shown). Polyfect (Qiagen) was used for 
transfection of HeLa cells according to the 
manufacturer’s instructions. 
 
 
Proliferation assay: 
Transfected VSMC were placed on 96 well culture 
plates and further cultured for 24 hours. Cells were 
then treated with [3H] thymidine (1 µCi/well) and /or 
MAPK inhibitors for 6, 24, 30hours. ERK MAPK 
inhibitor (PD98059), p38 MAPK inhibitor 
(SB203580) and JNK MAPK inhibitor (SP600125) 
were purchased from Calbiochem and used at 20µM 
for ERK and JNK MAPK inhibitors and 0.2µM for 
p38 MAPK inhibitor. After treatment, [3H] 
thymidine incorporation was measured by liquid 
scintillation counting. 
 
In Vitro wound healing assay, Time Lapse Video-
Microscopy (TLVM): 
Cells were transfected as described above, seeded 
into 35mm culture dishes and incubated overnight. 
Confluent cell monolayers were wounded by 
removing a strip of cells from the plate surface with 
a standard 1ml pipette tip. Wounded monolayers 
were washed with PBS to remove non-adherent cells 
and replaced with fresh complete growth medium. 
TLVM (30, 31) was used to film migration at the 
wound edges for 24 hours (1 frame every 
2.5minutes). 
The number of cells crossing a line marking the 
wound edges was counted over the 24 hour period. 
(Fig. 2D) 
15 randomly picked cells from the wound edges 
were tracked over a 1 hour period. The on-screen 
distance travelled was measured to calculate 
migration speed (mm/h) irrespective of direction. 
(Fig. 2E) 
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Western blotting: 
Anti-phospho-MAPK and anti-MAPK 
antibodies were purchased from Cell Signalling 
Technology and were used according to the 
manufacturer’s recommendations. Anti-β-actin 
antibody was from Dako. Between probing for 
the various proteins, membranes were stripped 
by Re-Blot Plus Mild solution (Chemicon). 
Membranes were developed with SuperSignal 
West Pico Chemiluminescent Substrate and 
signals were quantified by Chemigenius gel-
documentation system (Syngene). pMAPK and 
MAPK signals were expressed as a ratio to β-
actin levels within the same sample. 
 
Immunostainning 
Serial 4µm thick paraffin-embedded human 
artery sections were stained for Trb-1 using 
standard techniques. Trb-1 primary antibody 
(Millipore-Upstate) was applied overnight at 4 
oC. Sections were then exposed to goat 
biotinylated anti-rabbit secondary antibody 
(Vector laboratories) for 30 minutes at room 
temperature. Vectastain ABC reagent (Vector 
Laboratories) was added and incubated at room 
temperature for 30 min. Slides were then 
immersed in 0.25 mg/ml 3,3’diaminobenzidine, 
activated with hydrogen peroxide and 
counterstained with Carazzi’s hematoxylin. 
Primary antibody was omitted from the negative 
controls. 
 
RESULTS 
Tribbles expression is regulated in response to 
an inflammatory stimulus in hASMC 
Smooth Muscle Cell proliferation is a key event 
in the healing response to injury, a process 
which is initiated by inflammatory stimuli (32). 
To identify whether tribbles expression is 
regulated in vascular cells under inflammatory 
conditions, we stimulated human aortic smooth 
muscle cells (hASMC, Fig. 1A) and human 
umbilical vein endothelial cells (HUVEC, not 
shown) with LPS and measured tribbles mRNA 
expression levels by using qRT-PCR. IL-1β 
expression was measured as positive controls in 
the same samples (Fig. 1B). We found that trb-1 
was selectively and transiently up-regulated by 
LPS treatment in hASMC (Fig. 1A) but not in 
HUVEC (not shown). Previous reports (33) and 
our unpublished observations suggest that tribbles 
proteins may be unstable and expressed at low 
levels, therefore, mRNA levels are likely to correlate 
well with protein expression. We have, therefore, 
investigated the biological relevance of altered trb-1 
levels on hASMC under inflammatory conditions. 
To assess the role of trb-1 in LPS stimulated 
hASMC, we transiently transfected these cells with a 
trb-1 expression plasmid or a pool of anti-trb-1 
siRNA oligonucleotides and measured proliferation 
and migration in response to PDGF. However, first 
we evaluated the potential impact of culture 
conditions on trb-1 expression (Fig. 1C) and the 
specificity of the siRNA pool (Fig. 1D) used for 
targeting trb-1 mRNA. We have found that whilst 
trb-1 siRNA had the desired activity both under 
standard culture conditions (10% FCS) and when 
cells were serum starved post-transfection (0.5%), 
the expression levels of this gene and, indeed, the 
other tribbles as well (not shown) were significantly 
affected by the serum concentration. This is in line 
with previous work, demonstrating that expression 
of members of mammalian trb family is modulated 
through metabolic signals (34, 35). Therefore, we 
have used 10% FCS in all our experiments in order 
to minimise inter-experimental variations. In 
addition, the siRNA pools showed high specificity 
towards trb-1 and did not alter significantly trb-2 
and -3 expression (Fig. 1D). In line with these 
results, siTrb-1 treatment resulted in a substantial 
decrease in trb-1 protein levels (Fig. 1E) 
 
Tribbles-1 regulate specific hASMC cellular 
functions 
 To investigate the role of trb-1 in hASMC 
function, we raised or suppressed trb-1 levels by 
transient transfection of hASMC cells with trb-1 
expression plasmid or siRNA and measured 
proliferation by 3H-thymidine incorporation (Fig. 
2A-B). We observed a modest anti-proliferative 
effect at 48 hrs post-transfection (24 hrs time point 
in the proliferation assay) when trb-1 was 
overexpressed. In contrast, depletion of trb-1 results 
in a significant increase in proliferation rate at the 
same time-point (Fig. 2B). However, this assay 
measures the net effect of cell death and 
proliferation. In order to confirm that the observed 
increase in 3H-thymidine incorporation is due to an 
increased mitosis rate, we performed time lapse 
video imaging on control and si-trb-1 treated cells 
and calculated the rate of mitosis (Fig. 2C). The data 
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obtained by both methods was in agreement. In 
addition, there was not difference in the 
observed rate of apoptosis between treatment, 
further supporting a specific tribbles effect on 
proliferation. Using the same time lapse assay, 
we also measured VSMC migration in a “wound 
healing” assay. (Fig. 2D, E). These data show 
that neither the number of cells migrating into 
the wound (Fig. 2D) nor their migration speed 
(Fig. 2E) were affected upon depletion of trb-1. 
As trb-1 acts via modulating MAPK activation 
and this signalling system is known to govern 
VSMC proliferation, we used selective MAPK 
inhibitors to block individual pathways and 
investigated their involvement in the trb-1 
regulated proliferation (Fig. 2F). These data 
demonstrate that blocking of JNK but not p38 
pathways suppresses VSMC proliferation. In 
line with previous reports, inhibiting ERK 
activation also caused a significant inhibition of 
proliferation (36). 
To further investigate the impact of trb-1 levels 
in hASMC function, chemotaxic migration of 
these cells was measured in a transwell 
migration assay, in response to PDGF (Fig. 2G). 
Depletion of trb-1 led to an increase in 
transmigrated cells. Further, inhibition of the 
JNK pathway abrogated the effect of si-trb-1 
treatment, suggesting that trb-1 may be a 
negative regulator of hASMC chemotaxis via 
inhibitory activity of the JNK pathway. 
Activation of Vascular Smooth Muscle Cells by 
inflammatory signals leads to the production of a 
number of cytokines, including TNFα and 
TGFβ through MAPK mediated signalling 
events (37-41). We, therefore, investigated 
whether depletion of trb-1 had a modulator role 
in the production of these inflammatory 
cytokines, in VSMC. Our data show no 
difference in the dynamics or the amplitude of 
cytokine expression at the TNFα mRNA (Fig. 
2H) and TGFβ protein levels (Fig. 2I), implying 
that trb-1 may be a specific regulator of VSMC 
proliferation and migration.  
 
Overexpressed Trb-1 blocks AP-1 activation and 
Trb-1 depletion leads to constitutive JNK 
activation 
In order to gain mechanistic insight into the 
regulation of VSMC proliferation via the 
JNK/AP-1 pathways and trb-1, VSMC was 
transiently transfected with an AP-1 reporter 
plasmid, activated by overexpressed MEKK1 in the 
presence and absence of overexpressed trb-1 (Fig. 
3A). The results demonstrate that activation of AP-1 
can be blocked by overexpressed trb-1 in VSMC, in 
line with our previous report in HeLa cells (18). 
Next, the activation of the various MAPKs were 
assessed in control and trb-1 depleted cells. 
Phosphorylated MAPK (pMAPK, the activated 
form) and total MAPK levels were investigated in 
response to LPS treatment, by western blotting. 
pMAPK (Fig. 3B) and total MAPK (Fig. 3C) levels 
were normalised to β-actin and expressed as relative 
units. In agreement with our previous report (18), 
alterations in trb-1 levels had a differential impact on 
the various MAPK pathways. However, these effects 
were different in VSMCs, compared to those 
observed in HeLa cells (18). In VSMC, the amount 
of phospho-p38 protein but not the dynamics of 
activation was influenced by altered trb-1 
expression. In contrast, while ERK and JNK 
pathways were also sensitive to altered trb-1 
expression, these were no longer up-regulated by 
LPS stimulation. Indeed, modulation of trb-1 
expression caused phosphorylation of both of 
MAPKs to decrease, once stimulated. In addition, 
depletion of trb-1 mRNA by the siRNA constructs 
led to an increase in phosphorylation of JNK in the 
absence of any stimulus (Fig. 3B, middle graph, zero 
time point), suggesting that normal trb-1 levels 
inhibit the activation of this pathway in the non-
stimulated state. However, no significant alterations 
in total MAPK levels were observed in cells, where 
trb-1 levels were perturbed (Fig. 3C). These 
observations are compatible with the hypothesis that 
MAPK scaffold levels are key determinants of 
pathway activation (42) and that tribbles may have a 
scaffold-like function as proposed previously (18). 
According to these models, both up and 
downregulation of scaffold levels may lead to 
impaired activation of signalling systems. We have 
seen such effects on the JNK and ERK pathways in 
VSMC, similarly to our previous studies on HeLa 
cells (18). 
 
Trb-1/MKK4 interaction is key to the regulation of 
hASMC proliferation 
We have previously shown in biochemical assays 
that tribbles proteins interact with MAPKKs and 
regulate their activity (18). However, since many 
Kiss-Toth et al.: Trb-1 regulates smooth muscle cell function 6 
aspects of tribbles action appear to be cell type 
specific (for recent reviews see (43, 44)), we set 
out to investigate details of trb/MAPKK 
interactions in hASMC. Our data point to the 
JNK pathway as a key system in regulating 
proliferation and chemotaxis in these cells, in a 
trb-1 dependent manner. Therefore, we 
characterised the involvement of MKK4/SEK-1 
and MKK7, the two known MAPKKs, which 
lead to activation of JNK. Our results show that 
MKK4 but not MKK7 is expressed in these cells 
and that this expression pattern is not influenced 
by sitrb-1 treatment (Figure 4A). We also found 
that the phosphorylation of MKK4 was not 
affected by depletion of trb-1 (Figure 4B), 
suggesting that trb-1 directly interferes with 
MKK4 activity, rather than with activation 
and/or expression. To confirm the direct role of 
MKK4 in hASMC proliferation, we performed a 
[3H] thymidine incorporation assay in siMKK4 
treated cells (Figure 4C), as before. In line with 
our above model, the data demonstrate a positive 
role for MKK4, since depletion of this protein 
led to a decrease in proliferation rate.  
 To confirm the physical interaction 
between trb-1 and MKK4 in live hASMC, we 
used a yellow fluorescent protein (YFP)-based 
protein fragment complementation assay (PCA) 
(45, 46) and co-immunoprecipitation. The Venus 
variant of YFP was used in this assay, since it 
provides a higher signal than EYFP. MKK4 and 
Trb-1 were fused to the N-terminal fragment of 
Venus YFP (V1) or to the C-terminal portion of 
Venus YFP (V2), respectively. The two 
expression constructs were co-transfected and 
the YFP signal was visualised by fluorescent 
microscopy (Figure 4D). These data demonstrate 
that the MKK4/trb-1 complex is located 
predominantly in the nucleus of hASMC. In line 
with this finding, a co-immunoprecipitation 
experiment further confirmed the interaction 
between MKK4 and trb-1 (Fig. 4E).  
We have shown recently that the N-
terminal region of trb-1 governs the intracellular 
localisation of the protein (17). We wondered, 
therefore, whether the same domain influenced 
the location of the MKK4/trb-1 complex. 
Truncated trb-1 forms, lacking the N-terminal, 
the C-terminal or both domains (Figure 4F) were 
expressed as V2 fusion proteins (Figure 4E). 
The results show that the nuclear localisation of 
the complex is critically dependent on the presence 
of the N-terminal trb-1 domain. Mutants lacking this 
domain still showed an interaction with MKK4, but 
the signal was no longer preferentially nuclear. 
Further, these experiments demonstrate that the 
central, kinase-like domain of trb-1 is sufficient for 
interaction with MKK4. This is in line with our 
previous report, where we showed that expression of 
this domain was sufficient to inhibit of AP-1 
activation via trb-1 (17).  
In order to confirm specificity of the 
observed interaction, several control experiments 
were performed. Co-expression of an increasing 
amount of “unlabelled” trb-1 led to a dose-
dependent elimination of the YFP signal as detected 
by FACS (Figure 4G) or by fluorescent microscopy 
(Figure 4H). In addition, neither MKK4-Venus nor 
trb-1-Venus fusion proteins interacted with their zip-
Venus counterparts (these were used as positive 
control constructs in the system) (Figure 4G), which 
further supports the specific nature of this 
interaction. 
 
Tribbles-1 expression in atherosclerotic arteries 
Proliferation of vascular smooth muscle 
cells is one of the hallmarks of the development of 
chronic diseases of the vessel wall. In order to 
evaluate the potential role of tribbles in human 
disease, we studied segments of whole artery wall 
taken from the explanted hearts of patients 
undergoing cardiac transplantation for ischaemic 
heart disease (IHD) and characterised tribbles 
expression. Coronary arteries from patients with 
non-ischaemic dilated cardiomyopathy (DCM) were 
used as controls. In order to quantify potential 
differences in trb expression levels between the two 
groups, mRNA levels of known pro and anti-
inflammatory cytokines (IL-1β and IL-1ra) and 
tribbles 1-3 were quantified by using qRT-PCR (Fig. 
5). As in our previous work (47), we detected a “pro-
inflammatory phenotype” in the atherosclerotic 
group. Expression of trb-1 but not of trb-2 was 
significantly raised in the IHD group (Fig. 5A), 
whilst trb-3 expression was not detected in these 
samples (not shown).  
In order to visualise trb-1 expression in vivo, 
sections of a human coronary artery were stained by 
anti-trb1 antibody (Fig. 5B). The majority of trb-1 
specific staining was detected in the intimal and 
medial areas. Of note, nuclear and/or cytoplasmic 
trb-1 staining was observed in medial VSMC.  
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DISCUSSION 
 In this paper, we have evaluated the 
importance of tribbles proteins, particularly trb-1 
in the cellular responses of vascular smooth 
muscle cells to inflammatory stimuli. Taken 
together, our experiments demonstrate that trb-1 
is found in VSMC in vivo and that expression 
levels are key in modulating the extent of 
VSMC proliferation and chemotaxis. In contrast, 
VSMC migration speed in a “wound healing” 
assay and the production of cytokines are not 
affected by altered trb-1 levels, suggesting a 
specific physiological role for this protein. 
Whilst a body of literature supports the 
involvement of ERK and JNK MAPK pathways 
in VSMC chemotaxis, the role of these second 
messenger systems in wound healing assays (in 
the absence of chemokines) is much less 
understood. Our data implies that the two 
processes might be differentially regulated. 
However, further detailed studies will be needed 
to clarify this. 
 Blockade of specific MAPK pathways 
by pharmacological inhibitors pointed to the 
JNK pathway as a major regulator of VSMC 
proliferation. In line with the model where trb-1 
controls JNK activation, we found that si-trb-1 
treatment of VSMC led to the spontaneous 
activation of JNK (Figure 3B). Therefore, we 
have investigated the detail of the interaction 
between JNK activating kinases and trb-1. Of the 
MAPK kinases, which are known to activate JNK, 
MKK4 but not MKK7 was found to be expressed in 
VSMC. Using a recently developed technique 
(PCA), we were able to visualise the interaction 
between trb-1 and MKK4 in live VSMC cells. To 
our knowledge, this is the first use of this powerful 
technique in studies of primary vascular cells. A 
number of controls demonstrate the specificity of the 
observed interaction. Further, we were able to show 
that the intracellular localisation of the trb-1/MKK4 
complex is dependent on the N-terminal domain of 
trb-1. This is in line with our previous findings 
where we demonstrated that the N-terminal domain 
of trb-1 is essential for nuclear localisation. 
However, clarification of the functional relevance of 
this observation requires further studies. The use of 
truncated trb-1 proteins in PCA demonstrates that 
the kinase-like domain of trb-1 is essential for it’s 
ability to interact with MAPKKs. Since this domain 
is similar to that of the MAPKs (MAPKK 
substrates), a plausible hypothesis for the molecular 
mechanism of trb action is that tribbles may compete 
for the binding site with the MAPKs, thus regulating 
their activation. This model may explain why 
evolution preserved a catalytically inactive kinase 
domain from unicellular organisms to mammals (43, 
44). 
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FIGURE LEGENDS 
 
Figure 1: trb-1 expression in cultured human Aortic Smooth Muscle Cells. hASMC were stimulated 
by LPS for the various time points as indicated, total RNA was prepared and qRT-PCR was performed to 
detect changes in (A) tribbles 1-3 mRNA expression levels. (B) IL-1β  levels were also measured as 
positive controls in the same samples. (C) The impact of culture conditions on Trb-1 expression was 
assessed in control and si-trb-1 transfected hASMC cells by qRT-PCR. (D) The specificity of si-trb-1 
knockdown was evaluated by qRT-PCR, comparing expression levels of trb-1, -2 and -3 in si-trb-1 
transfected cells. The values were normalised to the expression of tribbles in cells transfected with control 
siRNA. (E) The efficiency of si-trb-1 treatment was assessed by western blot. Cells were transfected with 
control or trb-1 specific siRNA and western blot was performed on whole cell lysates using an anti-trb-1 
antibody. 
 
Figure 2. trb-1 function in hASMC proliferation, migration and chemotaxis. hASMC cells were 
transfected with a trb-1 overexpression construct (A) or si-trb1-1 siRNA (B). Proliferation rate was 
measured by 3H thymidine incorporation. As an independent measure of proliferation, time-lapse video 
microscopy was performed and the percentage of mitotic cells on each field were calculated (C). The 
number of cells migrated through the edge of the wound (D) and their speed of migration (E) was 
assessed in a wound-healing assay. (F) The effect of MAPK inhibitors on proliferation rate was measured 
as on panel B. (G) The number of cells migrated through the Boyden chamber in response to PDGF were 
compared between control and si-trb-1 transfected cells. In addition, the impact of JNK inhibitor on the 
migrating cells was also investigated. The impact of tribbles-1 knockdown on the expression of TNFα 
mRNA (H) and TGFβ protein levels (I) was evaluated by qRT-PCR and ELISA, respectively. 
 
Figure 3. Overexpression and suppression of trb-1 expression modulates activation of MAPK. (A) 
hASMC cells were transfected with AP-1 luciferase reporter, activated by the co-expression of pFC 
MEKK1 (both Stratagene) in the presence and absence of overexpressed trb-1, as indicated. (B) cells 
were transfected with empty vector (mock), trb-1 overexpression construct or si-trb1-1 siRNA, stimulated 
with LPS for 0-45 minutes, as indicated on the figure, lysed and pMAPK and β-actin levels were 
determined by Western blotting. (C) Unstimulaed cell lysates (0 time point) were used to detect the 
impact of altered trb-1 levels on steady state MAPK expression by Western blotting for total MAPK and 
β-actin. The signal intensity was quantified as above and expressed as a total MAPK/β-actin ratio. 
MAPK/β-actin levels in the mock transfected cells were taken as baseline (1 unit) and values measured in 
the si-trb-1 and overexpressed samples were plotted relative to these. 
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Figure 4. MKK4 - trb-1 interaction controls hASMC proliferation. (A) Expression of MKK4 and 
MKK7 in hASMC and the impact of trb-1 knockdown on the protein levels of these MAPKKs were 
assessed by Western Blotting. (B) Activation of MKK4 (30 mins, 100ng/ml LPS) was evaluated under 
normal and reduced trb-1 levels. pMKK4 values were normalised to actin and expressed as a ratio. (C) 
The ability of MKK4 to control hASMC proliferation rate was measured as on Figure 2 (24hrs post-
transfection). The efficiency of MKK4 knockdown was verified by western blot (Upper panel) (D) 
Physical interaction between MKK4 and trb-1 in hASMC was investigated by PCA. As positive controls, 
EGFP expression plasmid (left upper panel) and ‘zipper-PCA’ (left lower panel, zip-V1 and zip-V2) 
constructs were used. MKK4 was fused to the N-terminal fragment of Venus-YFP (V1), whilst trb-1 was 
expressed in fusion with the C-terminal fragment of Venus-YFP (V2). Representative cells show 
interaction between MKK4 and trb-1 (right panels). (E) To further confirm association between trb-1 and 
MKK4, co-immunoprecipitation was performed, using trb-1-myc expression construct. Lane 1: detection 
of MKK4 in a whole cell lysate. Lane 2: detection of MKK4 after anti-myc pull-down. (F) The impact of 
the N- and C-terminal domains of trb-1 on interaction with MKK4 in live cells and the location of the trb-
1/MKK4 complex was assessed by PCA. (G) The structure of trb-1 mutants and the positions of the N- 
and C-terminal deletions is shown. (H) To confirm the specificity of MKK4/trb-1 interaction, FACS was 
used to demonstrate the specific interaction between trb-1 and MKK4 in HeLa cells. Similarly to figure 
5E, an increasing dose of non-fluorescent trb-1 expression plasmid was co-transfected to compete out the 
labelled protein from the fluorescent complex. Further, no interaction was detected between control 
plasmids and either MKK4-V1 or trb-1-V2. (I) As a further control, an increasing dose of trb-1 
expression plasmid (unlabelled) was co-transfected in HeLa cells with the above two constructs (left) and 
the average total fluorescence per cell was measured (right) by fluorescent microscopy.  
 
Figure 5. trb-1 expression is up-regulated in IHD (A)Total RNA was prepared from sections of human 
coronary arteries from explanted hearts with IHD (n=8) (“Disease”) or DCM (n=6) (“Control”). qRT-
PCR was performed to quantify expression levels of major inflammatory cytokines and tribbles 1-3. 
Expression data was normalised for GAPDH as housekeeping control. Statistical analysis was performed 
by PRISM, using Student’s t-test. Relative expression values are presented using “box and whisker plots”. 
(B) Transverse sections of human coronary artery stained with trb-1 antibody. a) Haematoxylin and Eosin 
staining to show vessel architecture I intima, IEL, internal elastic lamina, M media; b) Trb-1 (brown 
staining) in intimal and medial areas, boxed area shown in d); c) control staining of a serial section with 
no primary trb-1 antibody; d) trb-1 staining to show individually stained VSMC (arrows).In a and b scale 
bar is 50µm; c and d scale bar is 25µm.   
 
Figure 6. The role of trb-1 in VSMC biology 
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